How AptarGroup Stock Has Been Performing

AptarGroup (ATR) has drawn renewed attention after a weaker stretch for the stock, with shares down 2.8% over the past day, 5.2% over the past week, and 12.2% over the past month.

Looking further back, the stock has fallen 19.6% over the past 3 months and 6.4% year to date, with a 1-year total return decline of 25.9%. Over 3 years, total return is roughly flat, and over 5 years the stock is down 18.2%.

Taken together, the recent 1 day share price decline and the weaker 1 month share price return suggest momentum has been fading, while the 1 year total shareholder return also sits in negative territory, pointing to a tougher period for longer term holders.

If you are comparing AptarGroup with other trends in the market, this is a good moment to see what else is moving and check out 19 top founder-led companies

With the stock under pressure yet trading at a reported 47% discount to an intrinsic value estimate, and about 42% below the average analyst price target, investors may ask whether this represents a potential opportunity or whether the market is already incorporating expectations about future growth.

Most Popular Narrative: 29% Undervalued

AptarGroup's most followed narrative places fair value at $161.43, above the last close of $114.67, framing the recent share price weakness against a higher long term estimate that is discounted at 7.10%.

The rapid expansion of AptarGroup's proprietary drug delivery systems, particularly in injectables for biologics, GLP-1, and central nervous system therapies, positions the company to benefit from rising global healthcare needs and an aging population. These high-value platforms support future revenue growth and margin expansion.

Curious what sits behind that valuation gap, and how revenue growth, profit margins and future earnings assumptions feed into it? The full narrative breaks down the numbers that underpin this fair value call, including how future earnings power and the chosen profit multiple interact to arrive at $161.43.

Result: Fair Value of $161.43 (UNDERVALUED)

However, this depends on pharma demand holding up, while ongoing intellectual property litigation costs and softer orders for emergency medicine systems could pressure earnings and sentiment.

Another View: What Earnings Ratios Say

AptarGroup screens as undervalued on fair value estimates, yet its current P/E of 18.9x is slightly above the fair ratio of 18.4x and meaningfully above both the global packaging industry at 15.4x and peer average of 15x. That premium suggests less margin for error if growth or cash flows disappoint, so how comfortable are you with paying up here?

Next Steps

With mixed signals on valuation and sentiment, it helps to look past headlines and see what stands out for you personally. If you want a quick way to weigh both sides, start with the 5 key rewards and 2 important warning signs

Ready For More Investment Ideas?

Before moving on, take a moment to line up a few fresh ideas so you are not relying on a single stock to drive your portfolio outcomes.

• Tap into potential growth with carefully selected lower priced stocks using the 27 elite penny stocks with strong financials.
• Zero in on companies that combine quality with attractive pricing through the 51 high quality undervalued stocks.
• Prioritise resilience and capital protection by filtering for sturdier balance sheets via the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.